The Predictive Scores for Gastric Cancer in Gastric Intestinal Metaplasia (GIM) Patient: a Recommendation for Thai Population
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01490541|
Recruitment Status : Unknown
Verified June 2012 by Rapat Pittayanon, MD, King Chulalongkorn Memorial Hospital.
Recruitment status was: Recruiting
First Posted : December 13, 2011
Last Update Posted : June 25, 2012
The predictive scores for gastric cancer in gastric intestinal metaplasia(GIM) patient: a recommendation for Thai population.
To evaluate major risk factors for gastric cancer in gastric intestinal metaplasia(GIM) patient in order to propose the appropriate recommendation for Thai people.
Single center, retrospective-cohort study.
|Condition or disease|
|Gastric Intestinal Metaplasia|
Study population and Sample size at Faculty of Medicine, Chulalongkorn University The patients who were diagnosed gastric intestinal metaplasia from 1997 to 2012 and then follow up for 5 years. Estimate sample size =280
- Investigational product, dosage & route of administration
- Questionnaire for explore the risk factors
- EGD with biopsy
- Blood sampling for gastro panel
- Duration of participation
- 5 years or until diagnose gastric cancer
|Study Type :||Observational|
|Estimated Enrollment :||280 participants|
|Study Start Date :||October 2011|
|Estimated Primary Completion Date :||December 2012|
|Estimated Study Completion Date :||October 2017|
|Gastric intestinal metaplasia patient|
- The prevalence of early gastric cancer in gastric intestinal metaplasia(GIM) patient from 5 year-follow-up in Thai population [ Time Frame: Up to 5 years ]In Thailand, gastric cancer patients usually presented with advance stage and carried the dismal prognosis. GIM is a well known precancerous lesion. The appropriate follow-up period in high risk GIM patient can increase the prevalence of early gastric cancer and reduce the mortality rate of gastric cancer
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01490541
|Contact: Rapat Pittayanon, MD||66813132112||Rapat125@gmail.com|
|Contact: Nuttaphat Namjud, M.Sc.||email@example.com|
|Bangkok, Thailand, 10330|
|Contact: Rapat Pittayanon, MD 66813132112 firstname.lastname@example.org|
|Contact: Nuttapaht Namjud, M.Sc 66894971957 email@example.com|
|Study Director:||Rungsun Rerknimitr, Professor||King Chulalongkorn Memorial Hospital|
|Principal Investigator:||Rapat Pittayanon, MD||King Chulalongkron Memorial Hospital|